Profitability Case Study
This study evaluates the financial impact of Retatrutide deployment within the Northern Arizona MedSpa corridor, comparing retail patient pricing against the Verified Vantage institutional fulfillment model.
1. REGIONAL RETAIL BASELINE (RETATRUTIDE)
| CLINIC / PROVIDER | RETAIL MONTHLY RATE | CALCULATED 2MG DOSE* COST (TO PATIENT) |
|---|---|---|
| Sedora Medical Spa | $479.00 | $119.75 / dose |
| Flagstaff Region (Avg) | $499.00 | $124.75 / dose |
| Regional "GLP Elite" Tiers | $679.00 | $169.75 / dose |
2. FULFILLMENT COST ANALYSIS (VERIFIED VANTAGE)
| ASSET GRADE | CASE PRICE (10 UNITS) | NET COST PER 2MG DOSE* |
|---|---|---|
| Retatrutide 10mg | $750.00 | $15.00 / dose |
| Retatrutide 20mg | $1,500.00 | $15.00 / dose |
| Retatrutide 60mg | $2,200.00 | $7.33 / dose |
By utilizing Verified Vantage infrastructure, practitioners capture a massive spread on the 2mg starting protocol:
• Entry-Level Profit: On a 10mg vial (providing five 2mg doses), the practitioner procurement cost is $15.00 per dose. Against a Sedona retail average of $119.75, this represents an 87.5% profit margin.
• High-Volume Yield (60mg): Utilizing a 60mg vial (30 doses) drops the procurement cost to $7.33 per 2mg dose, nearly doubling the available margin compared to entry-level vials.
• Strategic ROI: A single $750 case (10mg) provides 50 total doses. At a $499 monthly retail average (4 doses/month), this single case generates $6,237.50 in gross retail revenue.
View Trial Data: New England Journal of Medicine (NEJM)